Coleman et al. identify a robust gene regulatory network for patients with FLT3-ITD AML, highlighting a crucial role of several different transcription factors including RUNX1 in FLT3-ITD pathology and identifying drug-responsive AML-subtype-specific and overlapping regulatory modules. The gene discussed is RUNX1; the disease is acute myeloid leukemia.